Pierre-Marie is the Chief Executive Officer of the start-up Sinnovial, which is a biotechnology company created in September 2015 in partnership with Grenoble Alpes Hospital and University of Sciences. It is specialized in the development of innovative personalized medicine devices to improve the Chronic Inflammatory Rheumatism (CIR) management in rheumatology (especially rheumatoid arthritis and ankylosing spondylitis).
Sinnovial works towards these ends by providing its expertise and SinnoTest® technology (based on the analysis of patients’ proteomic profile and the calculation of treatment response probabilities ) to rheumatologists to contribute to the improvement of living conditions of people with Chronic Inflammatory Disease (CID).
The aim of SinnoTest® is to enable the physician to improve his patient management by maximizing successful biotherapy treatment from the initiation of the medical procedure.
Didier has over 25 years of broad international experience in the biotech and pharmaceutical industries as an executive leader in research and development, project management, GMP manufacturing, and business development. He joined Servier in April 2017 and prior to this, Didier started as a Research Scientist and Project Leader in Oncology at Rhône-Poulenc Rorer’s Gene Therapy Division, RPR-Gencell. He was subsequently Senior Director of Business Development at IDM-Pharma, then General Manager Cell Therapy where he leaded the international development of a cancer vaccine in the US and Europe; he also has served as Chief Development Officer at Biotechnol, as the CEO of Alfact Innovation and most recently Independent Consultant in Business Development to the bio-pharma and life
science industry. Didier has lived more than 15 years in the US and brings this culture to Servier.
Didier graduated with a Ph.D. in Molecular and Cellular Biology at University Louis Pasteur, Strasbourg, France, followed by a Post-doctoral internship at University of California Los Angeles UCLA (USA) in Medical Genetic Training Program and an Executive MBA at ESSEC, Paris.
PhD in Neuropharmacology (University Paris Descartes) and titular of a Master’s degree in Company Management (CNAM-International Institut of Management), Antony Lebeau has successively worked as research engineer (Inserm/Research Institut of Servier), project manager (GIS Prion-Ministry of Research, Inserm Transfert), communication manager (Inserm-Tranfert and Inserm-Transfert Initiative. He joined the French National Research Agency (ANR) as project manager in the of “Health Biology” department, working on Technology Transfer programs (RIB/Biotecs ,TecSan). He currently works as program officer in the ANR department of “Investments for the future and competitiveness”, working in the field of public-private partnerships. Antony Lebeau has been also expert for the European Commission and for the ERC in “Health and Biotechnology” and “Ethic and Governance” fields for the past 8 years.
Rafi Mardachti is a Pharmacist (Pharm.D) from the University of Paris XI (France). He has an MBA from the Albany College of Pharmacy of Union University (USA). He is a Master of Pharmaceutical Marketing from the University of Paris XI (France). He is the winner of the National Thesis prize in 1995: Mail Order Pharmacy.
His previous positions were: Regional District Manager at MEDCO (USA), Pharmacist Manager at Marionnaud (France), Health Manager Director at Quintiles (Europe). He is the founder and CEO of Universal Medica.
Rafi Mardachti has published various articles in specialized media and teaches at various schools and specialized Master’s degrees.
Nader Yaghoubi, M.D., Ph.D., is President and CEO of PathMaker Neurosystems, a clinical-stage neuromodulation company with operations in France and US. He has over 16 years of experience in the creation, operations and financing of life science companies. Prior to starting PathMaker, he was President and CEO of Symbiotix Biotherapies, a pioneering microbiome company emerging from Harvard Medical School. Before these, he was the first employee at Selecta Biosciences (Nasdaq:SELB) and BIND Therapeutics (Nasdaq:BIND), nanoparticle companies emerging from MIT. Previously, he was at Zero Stage Capital, a venture capital firm where he was responsible for investing in the life sciences sector, and was also an intern at Advent International. Dr. Yaghoubi received an M.D. and Ph.D. in Molecular Pharmacology from the combined degree program at Boston University School of Medicine. His doctorate work on the development of high-throughput automated electrophysiological systems resulted in five issued US patents, received one of his University’s highest awards for dissertational research, and was the basis of a venture-backed neuroscience company. He is extensively involved in mentoring young companies, and has served/serves as a mentor, advisor and reviewer with Massachusett’s Biotechnology Council’s MassCONNECT program, Mass Life Sciences Center programs, Springboard Venture Capital Forum and numerous university business plan competitions.